Abstract
AbstractNeuroblastoma (NB) is an embryonal deadly cancer in childhood driven by MYC or MYCN‐driven oncogenic signaling. The amplification of MYCN leads to malignant progression of NB and poor prognosis. Traditional chemotherapy is still a standard treatment for NB. Most of the cytostatic drugs take function in anti‐neuroblastoma. However, children with NB exhibit different clinical outcome variability and biological characteristics compared to adult patients. Given this, it is an urgent need to explore novel, safer and more efficacious treatments.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
